Kabra Drugs Ltd — Important, 30-05-2026: Company Update

Kabra Drugs announced strong audited financial results for the quarter and year ended March 31, 2026. The company reported full-year total income of ₹93.23 Cr, a significant jump of 14,463% year-over-year, with EBITDA at ₹5.82 Cr and PAT at ₹4.96 Cr, both turning positive from previous losses. For the fourth quarter, total income hit ₹35.52 Cr, up 5,448% YoY. Kabra Drugs is strategically expanding its pharmaceutical manufacturing and marketing, focusing initially on South India. Additionally, it plans to enter AI-led defence technologies, initiating necessary approvals and establishing an R&D facility. This marks a decisive shift towards accelerated growth and diversification.